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A presumptive diagnosis of bone metastasis can be easily made when a patient with a history of colorectal cancer develops 
bone lesions that are seen on follow-up imaging. In this case report, we describe a patient whose multiple bone lesions 
were wrongly attributed to a recurrence of rectal cancer rather than being identified as multiple myeloma lesions. When 
clinicians detect new, abnormal, bony lesions in a patient with a previous history of cancer, they should consider diseases 
such as multiple myeloma in their differential diagnosis. 
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INTRODUCTION
Skeletal bone is a frequent site of distant metastasis in patients 
with advanced solid cancers, such as breast, prostate, and lung 
cancers [1]. In contrast, primary colorectal cancer rarely metasta-
sizes to the bone late in its course [2, 3]. Regardless, a presumptive 
diagnosis of bone metastasis can be easily made when a patient 
with a history of colorectal cancer develops bone lesions that are 
seen on follow-up imaging. 
Multiple myeloma (MM) is a malignant neoplasm of plasma 
cells and mainly involves the bone marrow; it accounts for ap-
proximately 10% of hematologic malignancies [4]. The overall 
survival of patients with MM has improved significantly in the 
last decade with the emergence of thalidomide, bortezomib, le-
nalidomide, and hematopoietic stem-cell transplantation [4]. Al-
though plain radiographs of the skeleton are routinely used to as-
sess the extent of bone involvement, positron emission tomogra-
phy/computed tomography (PET/CT) and magnetic resonance 
imaging (MRI) are frequently added to increase the sensitivity or 
specificity of the diagnosis [4 ,5].
The coexistence of MM and colon cancer has rarely been re-
ported in the literature [6-9]. Because of their distinct treatment 
modalities, the ability of clinicians to distinguish MM from bone 
metastasis secondary to colorectal cancer is important. However, 
previous reports have demonstrated that despite advanced imag-
ing studies, discrimination between MM and bone metastasis 
from colon cancer is difficult [8, 9]. For that reason, this case re-
port describes a patient whose multiple bone lesions were wrongly 
attributed to a recurrence of rectal cancer rather than being iden-
tified as MM lesions. This misunderstanding resulted in a delay of 
appropriate treatment.
CASE REPORT
A 69-year-old male patient visited an outpatient clinic for his fifth 
annual follow-up. He had a history of rectal cancer for which he 
had undergone a long course of preoperative chemoradiotherapy, 
followed by a low anterior resection with colo-anal anastomosis. 
The pathology of the surgical specimen revealed proper muscle 
invasion without any regional or distant metastases (ypT2N0M0; 
yp stage I). Adjuvant chemotherapy, based on a regimen contain-
ing 5-fluorouracil (FU), was given 4 times.
At the fifth annual follow-up, the following tests were per-
formed: serum carcinoembryonic antigen (CEA), colonoscopy, 
pelvic MRI, and PET/CT. The colonoscopy showed no evidence 
of local recurrence. The patient’s CEA level was 1.5 ng/mL. How-
ever, pelvic MRI revealed multiple, newly developed, small nod-
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ules in the pelvic bones that were suggestive of bony metastases 
(Fig. 1). The PET/CT scan also showed multiple hypermetabolic 
foci in the bilateral humerus, femurs, scapulae, ribs, spine and 
pelvic bones (Fig. 2). Further study using Tc-99m methylene di-
phosphonate (MDP) whole-body bone images showed increased 
uptake in the right anterior sixth rib, the spinous process of T9, 
and the upper portion of the bilateral sacroiliac joints (Fig. 3). 
Under a presumptive diagnosis of bone metastases from rectal 
cancer, palliative chemotherapy with the XELOX regimen 
(capecitabine, 5-FU and oxaliplatin) was planned. However, che-
motherapy was delayed for approximately five weeks due to ab-
normal laboratory findings, including anemia, leukocytopenia 
and mildly-elevated serum creatinine (Cr). After the first dose of 
XELOX chemotherapy, the patient was noted to have pancytope-
nia and a gradually-rising serum Cr level. The patient also suf-
fered from poor oral intake and nausea. These clinical manifesta-
tions and abnormal laboratory findings were attributed to the ad-
verse effects of XELOX chemotherapy. Therefore, further chemo-
therapy could not be given. The pancytopenia and the elevated 
serum Cr persisted for 2 months after the last chemotherapy dose. 
The patient was transferred to the Department of Nephrology to 
evaluate his elevated Cr levels. Initially, the patient was suspected 
to have contrast-induced acute kidney injury or chemotherapy-
induced chronic renal disease. A 24-hour urine study detected a 
large amount of protein. Urinary immunoelectrophoresis demon-
strated a monoclonal gammopathy with an M spike. Further-
more, urinary immunofixation electrophoresis revealed an ab-
normal band in the kappa lane. Serum protein electrophoresis 
showed hypogammaglobulinemia (680 mg/dL) with an elevated 
free kappa light chain (6,090 mg/L). 
The above results led us to perform a bone marrow biopsy for 
suspected MM. The biopsy revealed hypercellular marrow parti-
cles with marked plasmacytosis (88.3% of absolute neutrophil 
counts). Based on these results, a final diagnosis of MM (kappa 
Fig. 1. Pelvic magnetic resonance imaging revealed newly developed, 
multiple, small, nodular lesions in the pelvic bone (white arrow-
heads).
Fig. 2. Positron emission tomography/computed tomography scans 
demonstrated newly developed, multiple, hypermetabolic foci in the 
bilateral humerus, femurs, scapulae, ribs, spine and pelvic bones 
(black arrows). 
Fig. 3. Tc-99m methylene diphosphonate showed increased uptakes 
in the right anterior sixth rib (black arrow), spinous process of T9 
(white arrowhead), and upper portion of the bilateral Sacroiliac 
joints (black arrowhead).
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type) was made. Chemotherapy was initiated with a combined 
regimen of bortezomib, melphalan and prednisone (VMP regi-
men) every 35 days. A 50% reduction of in the recommended 
dose of mephalan and prednisone were initially administered due 
to chronic renal failure. During the first cycle of the VMP regi-
men, we reduced the dose of bortezomib by an additional 75% 
because the patient experienced severe diarrhea. After the fifth 
cycle of chemotherapy, the hypogammaglobulinemia (720 mg/
dL) with free kappa light chain elevation (587 mg/L) improved, 
suggestive of a partial response. Eight cycles of the VMP regimen 
were completed. The patient was offered an additional 12 cycles 
of cyclophosphamide, thalidomide and dexamethasone (CTD 
regimen). However, the disease had progressed. Unfortunately, 
the patient could not tolerate further chemotherapy (including 
low dose dexamethasone with lenalidomide) and was lost to fol-
low up. 
DISCUSSION
A few prior studies have reported the coexistence of MM and co-
lon cancer [6-9]. However, to the best of our knowledge, this is 
the first case of MM mimicking bone metastases from rectal can-
cer. In this case, a presumptive diagnosis was made based on the 
patient’s history of rectal cancer and the presence of multiple bony 
lesions on imaging.
MM causes approximately 1% of all malignancies and is increas-
ing in prevalence annually. Most patients undergo an asymptom-
atic period, defined as monoclonal gammopathy of undetermined 
significance (MGUS). At a rate of approximately 1% per year, 
MGUS progresses to myeloma [4]. MM may present with the fol-
lowing signs of end-organ damage: hypercalcemia, renal insuffi-
ciency, anemia, and bone lesions (including lytic lesions and os-
teopenia) [5]. Although the patient described here had thrombo-
cytopenia and elevated serum Cr, these abnormal laboratory 
findings are not specific to MM. Furthermore, the prolonged 
pancytopenia and elevated Cr were thought to have resulted from 
the first cycle of XELOX chemotherapy. These clinical situations 
resulted in a delay in the proper diagnosis and management. 
Recent reports have demonstrated that most patients with bone 
metastasis from colorectal cancer have initially advanced stages 
(stage III or IV), high levels of CEA at the time of diagnosis, and a 
median time interval to bone metastasis of 10–11 months [2, 3]. 
In addition, isolated bony metastases without the involvement of 
another organ, such as the liver or the lungs, are rare [2, 10]. In 
this case, the patient had stage I rectal cancer postoperatively, with 
no elevation of the CEA level (2.1 when rectal cancer was diag-
nosed, and 1.5 when MM was diagnosed). No other metastatic le-
sions, except those in the bone, were present. Furthermore, al-
most 5 years had elapsed between the initial resection of the pri-
mary tumor and the detection of possible recurrence. If the bony 
lesions were truly metastases from rectal cancer, the patient’s pre-
sentation would be considered extremely rare and inconsistent 
with each subcategory of bone metastasis from colorectal cancer. 
Even though, the clinician, depending on a thorough review of 
radiologic imaging and multidisciplinary discussion, considered 
bone metastasis as a priority of diagnosis.
In the diagnosis of MM, whole body X-ray (WBXR), CT, MRI, 
radionuclide imaging, and PET/CT are currently used. That Tc-
99m MDP may not detect all lesions in MM is well known [11]. 
PET/CT or PET is useful in the detection of occult lesions that are 
invisible in Tc-99m MDP. When the Durie-Salmon PLUS staging 
system is used, PET/CT or PET imaging is required [5]. Although 
PET scans have a superior detection rate for bone lesions com-
pared to WBXR, the superiority of PET/CT in comparison to 
MRI has not yet been established [5]. Shortt et al. [12] reported 
that when PET and whole-body MRI were used in combination 
with concordant results, the positive predictive value was 100%. 
However, data addressing the sensitivity or the specificity of di-
agnostic modalities in discriminating MM from bone metastasis 
are limited, potentially given its rarity. The incidence of bone me-
tastases from primary colorectal cancer is relatively low (less than 
10%) compared to that of other solid tumors. The most common 
sites for skeletal metastases are the vertebral column, particularly 
the lumbar and the sacral portions, followed by the pelvic bones 
and ribs [2, 3, 13, 14]. The radiologic findings usually demon-
strate osteolytic or mixed osteolytic-osteoblastic patterns, resem-
bling the patterns described in our case. For this reason, previous 
case reports have also demonstrated that distinguishing between 
MM and bone metastasis, even with the addition of PET/CT 
scans, is difficult [8, 9]. Considering the diagnostic challenges, 
this case emphasized the importance of considering MM as a po-
tential diagnosis in the assessment of rectal cancer patients with 
bone lesions. This is particularly true in patients with somewhat 
unusual clinical presentations.
In conclusion, this case highlights the rarity of detecting MM on 
routine annual follow-ups for rectal cancer, in contrast to the rela-
tively frequent diagnosis of bone metastasis from rectal cancer. 
When clinicians detect new abnormal bony lesions in a patient 
with a previous history of cancer, they should consider diseases 
such as MM in their differential diagnosis. 
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